Sandip Kapadia, the Chief Financial Officer of Harmony Biosciences Holdings , Inc. (NASDAQ:HRMY), a pharmaceutical company ...

The stock of Vertex Pharmaceuticals Incorporated VRTX has declined almost 13% in the past six months. A key reason for the stock price decline was unimpressive data from a phase II study on its key ...

Helius Medical Technologies, Inc. (Nasdaq: HSDT) announced it has exceeded its initial enrollment target for the stroke registrational program evaluating its Portable Neuromodulation Stimulator (PoNS® ...

The US healthcare system under Trump 2.0 are likely to benefit Indian players, except for the push for increased US drug ...

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral antidepressants. On Tuesday, the Food and Drug Administration (FDA) ...

Shares of Ionis Pharmaceuticals (NASDAQ:IONS) climbed 7% today after the company announced that regulatory agencies in the ...

Discover the potential of Ispire's innovative cannabis products and holistic solutions, a hidden gem in a competitive market with room to grow.

Surmodics, Inc. SRDX demonstrated strong performance in the last reported quarter. Its loss per share was 51.9% narrower than ...

MaxCyte Inc. (NASDAQ: MXCT) is a global developer of next-generation cell therapies. They provide crucial technology for cell ...

Exelixis, Inc. (NASDAQ:EXEL), currently trading near $33, continues to build on the success of its flagship product ...

Inhibrx Biosciences , Inc. (NASDAQ:INBX), a clinical-stage biopharmaceutical company valued at $205.41 million, is navigating a critical phase in its development as it advances its oncology pipeline.